Market Access & Ecosystem Insight
Understand the system before it decides for you.
The Problem We Solve
An early, honest read of the European access and adoption landscape — so evidence, pricing and engagement choices are made with open eyes.
You call us when you're entering France, Switzerland or the wider European market and the access pathway is a black box. When evidence-generation plans were designed for regulators, not payers or prescribers. When adoption is slower than the clinical value suggests — and nobody agrees why. Or when you need the ecosystem mapped before committing field resources.
Deliverables:
Stakeholder and decision-pathway map
Access and pricing-logic orientation, market by market
Adoption-barrier diagnosis
Evidence-to-value gap analysis
Engagement prioritiesrformance dashboard
How it works
Step 1
Landscape
The access architecture of your target markets: who decides, on what logic, on what timeline.
Step 2
Stakeholders
The real decision pathway mapped — payers, prescribers, institutions — beyond the org charts.
Step 3
Gaps
Where your evidence and value story fall short of what the system will ask, and what closes the distance.
Step 4
Priorities
The engagement sequence that fits your resources, with the trade-offs stated plainly.
You call us when the data is strong but the value story changes depending on who tells it. When partnering or fundraising discussions are coming and the commercial narrative lags the science. When an established standard of care makes differentiation harder than the clinical profile suggests. Or when a brand plan exists on paper but does not drive choices in the field.
Behind this practice: go-to-market leadership for a subcutaneous device and a rare-disease indication within a franchise that grew from $1B to $4.5B — and launch-team leadership for new indications and formulations on one of the world's largest biologics.
